Background-Soluble ST2 (sST2), a biomarker related to inflammation, is associated with outcomes of patients with heart failure. In-depth analyses of the relationship among sST2, changes in sST2, and patient outcomes are reported. Methods and Results-sST2 was measured at baseline (n=1650), 4 months (n=1345), and 12 months (n=1094) in Valsartan Heart Failure Trial. Baseline sST2 averaged 28.7±16.2 ng/mL, significantly (P<0.001) higher in men than women but supranormal in only 9% and 15%, respectively. A continuous relationship between sST2 and the log hazard ratio for outcomes was modeled as 2 linear segments with a significant decrease in the rate of increase in hazard ratios >33.2 ng/mL. Each segment of the sST2 distribution was significantly (P<0.0001) associated with the risks of morbid event, mortality, and hospitalization for heart failure. Only sST2 values <33.2 ng/mL were significantly related to the outcomes when 23 readily available clinical variables including N-terminal probrain natriuretic peptide were included in the Cox regression model. sST2 did not improve discrimination of patient outcomes. Compared with placebo, valsartan significantly (P<0.001) reduced the rate of increase in sST2. Increases in sST2 for 12 months, but not decreases, were significantly associated with subsequent outcomes, independent of clinical variables, sST2, and valsartan treatment. Conclusions-In this study, baseline sST2 was nonlinearly associated with patient outcomes but did not provide substantial prognostic information when added to a clinical prediction model that included N-terminal probrain natriuretic peptide. An increase but not decrease in sST2 was independently associated with outcomes. Additional research is needed to determine whether monitoring ST2 levels can improve patient outcomes. (Circ Heart Fail. 2014;7:418-426.)
S
T2 is a member of the toll-like/interleukin-1 receptor super family that exists in a membrane bound (ST2 ligand) and soluble circulating form (sST2). 1 The cytokine interleukin-33 (IL-33) is the ligand for this receptor that is a mediator of inflammation in several diseases including asthma, rheumatoid arthritis, pulmonary fibrosis, and collagen disease. 1 More recent findings suggest that the IL-33/ST2 system may also play an important role in pathogenesis of cardiovascular disease. 2 The IL-33 ligand and both ST2 ligand and sST2 are upregulated in fibroblasts and cardiomyocytes after myocardial infarction (MI). 3 Administration of recombinant IL-33 to cultured rat neonatal cardiomyocytes prevents the prohypertrophic effects of angiotensin-II or phenylephrine. However, administration of sST2 reversed this antihypertrophic effect. 2 These findings suggest a possible role of the circulating sST2 not only as a biomarker of cardiac mechanical overload but also as a possible mediator of cardiac pathology. sST2 levels are elevated in cardiovascular conditions including MI 3, 4 and acute heart failure (HF) 5, 6 but less so in chronic HF [7] [8] [9] and are associated with worse patient outcomes. However, it is unclear how sST2 values change over time and whether changes in sST2 are related to subsequent outcomes. Furthermore, because angiotensin-II increases sST2 signaling, 3 whether its blockage with valsartan affects sST2 levels and thereby alters outcomes is not known.
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The reference range for sST2 is significantly higher in normal men (8.6-49.3 ng/mL) than women (7.2-33.5 ng/mL). 10 Thus, the prognostic information provided by sST2 may depend on sex.
In this post hoc analysis, we (1) examine the relationships between baseline clinical variables and baseline sST2 levels and 12-month changes in sST2; (2) model relationships between sST2 and outcomes, testing for differences between men and women; (3) determine whether sST2 added clinically significant prognostic information to a prediction model composed of readily available clinical assessments including N-terminal probrain natriuretic peptide (NT-proBNP); (4) examine how valsartan affected sST2 over time; and (5) model the relationship between 12-month changes in sST2 and subsequent outcomes. 
Methods

Study Design and Patients Selection
The Valsartan Heart Failure Trial (Val-HeFT) was a randomized, placebo-controlled, double-blind trial that enrolled 5010 patients with New York Heart Association class II to IV HF, ejection fraction <40%, to evaluate the efficacy of valsartan. Val-HeFT had 2 primary end points: all-cause mortality and the first morbid event that was a composite of death, sudden death with resuscitation, hospitalization for HF, or administration of intravenous inotropic or vasodilator drug for 4 hours or more without hospitalization. 11 Valsartan had no effect on mortality but reduced the first morbid events by 13% and hospitalizations for HF by 28%. The study was approved by the institutional review board at each center, and all subjects provided a written informed consent.
sST2 Measurements
The levels of sST2 were measured on plasma stored at −70°C in patients enrolled only in the United States using the Presage ST2 ELISA by Critical Diagnostics, San Diego, CA. 12 On average, each aliquot had been thawed and refrozen thrice; the assay used is Food and Drug Administration-cleared, and sST2 is stable for ≥15 freezethaw cycles.
Statistical Methods
Baseline characteristics are described using means and SDs, quartiles, or proportions expressed as percentages as appropriate for the level of measurement and distribution of the variable. Natural logarithms were used to analyze variables with substantially skewed distributions. Levels of sST2 in the men and women were compared using a t test. Relationships between baseline and changes in sST2 levels and other baseline variables were examined using linear regression including interactions with sex.
The relationships between baseline and changes in sST2 levels and morbid events, all-cause mortality, and hospitalizations for HF were analyzed using Cox proportional hazards regression models. After preliminary analyses using restricted cubic splines to examine the nature of the continuous relationships between sST2 and the logarithm of the hazard ratio (lnHR) of study outcomes, the sST2 levels were modeled as a continuous segmented variable, thereby estimating the rate of linear increase (slope) in the natural lnHR per ng/mL of sST2 within each of 2 segments below and above the 75th percentile of the ST2 distribution (33.2 ng/mL). 13 ln(HR)=β 1 (sST2 <33.2 )+β 2 (sST2 >33.2 ), where HR is the hazard ratio and the βs are regression coefficients representing a linear slope for each segment of the sST2 distribution.
Similar approaches were used to analyze changes in sST2 during the first year of follow-up that led to using 2 spline variables to represent changes in sST2 as either decreases or increases. The proportional hazards assumption that the value of the regression coefficient (β), that is, slope in each segment of sST2, did not change during follow-up was examined by analysis of Schoenfled residuals. Tests for interactions were conducted to determine whether the rate of increase in the lnHR within each of the 2 segments of baseline sST2 differed by sex.
To evaluate whether the baseline sST2 spline variables provided additional prognostic information, they were added to a Cox regression model containing 23 clinical correlates of outcomes including age, sex, New York Heart Association class, ejection fraction, diabetes mellitus, atrial fibrillation, ischemic heart disease, body mass index, systolic blood pressure, orthopnea, heart rate, serum sodium, albumin, hemoglobin, uric acid, estimated glomerular filtration rate, use of an angiotensin-converting enzyme-I, β-blocker, diuretic, digoxin, spironolactone, the Val-HeFT treatment allocation, and NT-proBNP. Natriuretic peptides were included in the clinical model because they are now routinely measured and associated with patient outcomes. The likelihood ratio statistic was used to determine whether adding the spline variables representing sST2 added significant information. 14 The improvement in discrimination of subjects that did or did not have an outcome event was assessed by changes in Harrell C index and the noncategorical version of the net reclassification improvement for time-to-event analyses. [15] [16] [17] For the net reclassification improvement calculation, any size increase or decrease in model-based estimates of individual predicted probabilities was used to indicate an upward or downward movement regardless of whether the changes in predicted probabilities would be clinically meaningful. Predicted event-free survival curves for varying values of sST2 at mean values of the other covariates are shown to depict the prognostic information provided by sST2.
A B Figure 1 . Relationship between soluble ST2 (sST2) and the risk of a morbid event in a Cox regression model with sST2 as the only predictor. A, Segmental linear relationship to the logarithm of the hazard ratio, and (B) the exponential relationship to the hazard ratio at different levels of baseline sST2. ACE indicates angiotensin-converting enzyme; BMI, body mass index; BNP, B-type natriuretic peptide; BP, blood pressure; eGFR, estimated glomerular filtration rate; Gal-3, galectin-3; GDF-15, growth differentiation factor-15; H/o, history of; hs-CRP, high-sensitivity C-reactive protein; hs-TnT, high-sensitivity troponin T; JVD, jugular venous distention; LVEF, left ventricular ejection fraction; LVIDD/BSA, left ventricular internal diastolic dimension corrected for body surface area; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NT-proBNP, aminoterminal probrain natriuretic peptide; NYHA, New York Heart Association; PND, paroxysmal nocturnal dyspnea; PRA, plasma renin activity; and S3, third heart sound.
*The regression analysis used natural logarithms because of skewed distribution. Longitudinal linear regression of the baseline, 4-month, and 12-month sST2 measurements was used to analyze differences in changes in the valsartan and placebo groups. A 3-way test for interaction of treatment, time, and sex was done to determine whether valsartan effect differed by sex. Results of the fixed effect model of the within-subject variation are reported. These analyses were clustered by subject to adjust the standard errors of the estimates for the within-subject correlation between repeated measurements of sST2.
A P<0.05 was considered statistically significant without adjustment for the number of comparisons being made during these exploratory analyses of data from a randomized controlled clinical trial. All analyses were done using version 12.1 of Stata software.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the article as written.
Results
Baseline Patient Demographics in Relation to sST2
At baseline, the mean sST2 level was 28.7±16.2 ng/mL (1254 men and 396 women); median 24.6 (interquartile range, 19.0-33.2) ng/mL. The sST2 levels were significantly higher in men than women (30.0±16.5 versus 24.1±14.1 ng/mL; P<0.0001). Only 9.2% (119 of 1290) of men had sST2 levels above the previously reported normal range for men (49.3 ng/ mL) compared with 15% (54 of 360) of women above the normal range for women (33.5 ng/mL). Table 1 shows the baseline characteristics and their association with sST2. Baseline characteristics were generally similar in men and women except for presence of more New York Heart Association class III/IV, orthopnea, edema, and third heart sound in women and worse renal function in men. Several variables were significantly associated with the baseline levels of sST2. The mean difference in the baseline sST2 levels between men and women of 6.0 (95% confidence interval [CI], 4.1-7.9) ng/mL could not be explained when multivariable regression was used to adjust for all of the differences in baseline characteristics (5.9 [3.9-7.9] ng/mL). The sex difference was moderated by several baseline characteristics and was substantially greater among patients with paroxysmal nocturnal dyspnea and less so with lower body mass index (Table  II in the Data Supplement). The sex difference increased as levels of high-sensitivity C-reactive protein and GDF-15 increased. Diabetes mellitus attenuated the sex differences as did treatment with a β-blocker.
Association Between Baseline sST2 and Patient Outcomes
During a median follow-up of 23 months (interquartile range, 17-30 months), 346 (21%) died (22% men and 18% women), 558 (34%) had a first morbid event (34% men and 32% women), and 312 (19%) had a hospitalization for HF (18% men and 21% women). The modeled relationship between sST2 and the lnHR and the corresponding HR's for the first morbid event are shown in Figure 1A and 1B. This Cox model of sST2 levels alone was significantly better than a model with no prognostic variables (P<0.0001, likelihood ratio test with 2 degrees of freedom). This model's Harrell C was 0.61. Table 2 lists the unadjusted estimated rates of increases in the lnHR per ng/mL of sST2 (ie, the Cox model regression coefficients [β, slope] within each segment of sST2 levels). For each study end point, the rate of increase in lnHR when the sST2 was <33.2 ng/mL, that is, within the normal range for both men and women, was significantly †P=0.03 for difference between men and women tested as an interaction between sST2 and sex in the Cox regression model of the relationship between sST2 and study end points.
>0 and significantly (P<0.001) greater than the slope >33.2 ng/ mL. However, the slopes >33.2 ng/mL were significantly >0, and the HR continued to increase with sST2. Below 33.2 ng/ mL, the rate of increase in the lnHR of HF hospitalizations was >2× greater in women (β 1 , 0.085; 95% CI, 0.051-0.12) than men (β 1 , 0.041; 95% CI, 0.019-0.062; P=0.03), whereas there was no difference in the slopes for mortality and a nonsignificant difference for the composite of first morbid event. The lnHR-sST2 slopes >33.2 ng/mL were not significantly different between men and women for any outcome.
Addition of sST2 to Clinical Prognostic Variables
Baseline sST2 added significant information to the Cox regression model of first morbid events composed of 23 clinical variables including NT-proBNP and the Val-HeFT treatment allocation (Table 3 ; likelihood ratio test P=0.005). However, the significant sST2 variable representing values <33.2 ng/mL did not improve discrimination with no change in Harrell C. The net reclassification improvement during the first year of follow-up increased mostly in the group that had an event with little change in the group that did not have an event. Most of the changes in individual predicted probabilities were small; the median (interquartile range) change in the group that had a morbidity or mortality event being <0.001 (−0.011 to 0.014) and 0.005 (−0.014 to 0.020) in the event-free group. The predicted survival times free of a morbid end point for selected values of sST2 are shown in Figure 2 .
Changes in sST2 and Effect of Valsartan
The levels of sST2 measured at baseline, 4 months, and 12 months in patients with data at any or all 3 time points are summarized in Table 4 . Overall 82% (n=1357) had ≥2 sST2 measurements for estimating longitudinal trends. On average, for patients with data at any visit, there was a significant upward trend in sST2 levels in the placebo group (slope 4.7 [95% CI, 3.0-6.4] ng/mL per year). Valsartan significantly reduced this trend to 0.8 (95% CI, −0.2 to 2.0) ng/mL per year (P<0.0001 for treatment and time interaction). Similar results were seen when the analysis was restricted to patients with data at all time points (Table 4; Figure 3 ). Sex did not significantly moderate the valsartan effect.
Controlling for treatment with valsartan, age and baseline sST2, history of ischemic heart disease, atrial fibrillation, diabetes mellitus, New York Heart Association class, uric acid, plasma renin activity, hs-troponin, galectin-3, and GDF-15 were all positively correlated with the overall changes in sST2 after 12 months, whereas systolic blood pressure, albumin, hemoglobin, and estimated glomerular filtration rate were inversely related. Each of these variables alone only explained 3% to 5% of the variation in changes in sST2 for 12 months. Nevertheless, many of these relationships suggest that patients with higher risk of events at baseline were more likely to have an increase in sST2. The increase in sST2 at month 12 was NRI-noncategorical net reclassification improvement indicating the net fraction that had any increase in predicted probability among those that had events (potential change in sensitivity), the net fraction that had any decrease in predicted probability among those that did not have an event (potential change in specificity), and the sum of NRI subgroups. HF indicates heart failure; and sST2, soluble ST2. Table 3 .
associated strongly with the occurrence of nonfatal events, predominantly hospitalizations for HF between month 4 and 12 (mean increase in sST2 of 13 ng/mL; P<0.001 after adjusting for the effects of valsartan and baseline sST2). The 12-month changes in sST2 in the placebo and valsartan group remained significantly different after controlling for the effects of interim events (4.1 versus 0.7 ng/mL per year; P=0.001).
Changes in sST2 From Baseline to 12 Months and Subsequent Events
On follow-up day 364, there were 1013 patients who were event free and had measurements of sST2. Of these, 199 (20%) had a subsequent morbid event, 124 died (12%), and 108 (11%) had a HF hospitalization. Of the 1013 patients, 628 (62%) had an increase in sST2 (quartiles of increases=2.4, 5.0, and 8.4 ng/mL) and 385 (38%) had a decrease in sST2 (quartiles of decreases=−9.1, −4.4, and −1.7 ng/mL). Changes in sST2 during the first year of follow-up were modeled using 2 linear spline variables representing decreases and increases in sST2. The modeled relationship between these increases and decreases in sST2 and the subsequent lnHR and the corresponding HR's for the first morbid event are shown in Figure 4A and 4B. Whereas, for a 1 ng/mL rise in sST2, the slope of lnHR increased significantly (β=0.028; 95% CI, 0.020-0.035; P<0.0001), a decrease in sST2 was associated with little or no effect on lnHR (β=0.003; −0.014 to 0.020; P=0.72). Similar findings were seen for mortality and hospitalization for HF (data not shown).
As shown in Table 5 column 2, when the changes in sST2 from baseline to 12 month were added to the baseline clinical model including baseline sST2, the increases in sST2 were associated with a significant increase in risk for all subsequent outcomes, whereas decreases in sST2 were not associated with significant decrease in subsequent risk. Adding the 12-month changes in sST2 increased the model discrimination as indicated by increases in Harrell C (0.71-0.74) and the total net reclassification improvement. Figure 5 shows corresponding predicted risk of subsequent morbid event for a 5 ng/mL increase, 5 ng/mL decrease, or no change in sST2.
Whereas 12-month change in sST2 improved the model discrimination when added to the baseline clinical model, the same 12-month changes in sST2 did not improve the model composed of the clinical variables reassessed at month 12 including the value of sST2 at 12 months. This suggests that knowing by how much the sST2 level had decreased or increased at month 12 from baseline did not add significant prognostic information to 12-month assessments alone (Table 5 column 3) . However, judging by the Harrell C indexes, the model composed of 12-month assessments alone provided better discrimination of all subsequent events than the baseline model plus 12-month changes in sST2 (0.77 versus 0.74 for the first morbid event).
Discussion
This is the largest study of sST2 in HF and confirms previous reports that sST2 is related to subsequent morbid events. [5] [6] [7] [8] [9] Interestingly, in this study, the most rapid increase in the estimated hazard ratios was seen below sST2 levels of 33.2 ng/ mL (ie, within the reported normal range for both men and women). 10 Thereafter, the hazard ratios continued to increase significantly with sST2 levels albeit at slower rate. Although sST2 levels were significantly higher in men than women, the relationship between sST2 and the hazard ratios did not differ significantly between men and women with the exception of HF hospitalizations in the range of sST2 <33.2 ng/mL. These findings, therefore, do not support a need to interpret the prognostic information provided by sST2 differently for men and women, although the levels and normal range do differ. 10 Only 9% of men and 15% of women in this sample had supranormal Table 4 .
levels, and these results may not generalize to patients with higher levels of sST2 as seen during acute HF or MI. Although the sST2 levels in this study were similar to other reports of chronic HF, 7-9 levels of sST2 in patients with acute HF and post-MI are significantly higher but fall rapidly over days to weeks. 5, 6, 18, 19 This may be part of an acute neurohormonal and inflammatory stress response that may not be present in clinically stable HF such as those enrolled in Val-HeFT.
Baseline Correlates of sST2
At baseline, sST2 was most strongly related to several markers of HF, reflecting different pathophysiological pathways such as inflammation and tissue injury (GDF-15 and high-sensitivity C-reactive protein), myocardial stretch (NT-proBNP), cardiac fibrosis (galectin-3), and myocyte necrosis (hs-troponin). An explanation for the strong relationship between sST2 with GDF-15 (R 2 =0.22) is not obvious. Proinflammatory cytokines have been shown to enhance the expression of GDF-15 in cardiaomyocytes, 20 and sST2 was independently associated with high-sensitivity C-reactive protein in the present study, supporting a link between sST2 and inflammation.
The sST2 levels did not correlate with LV dimensions. Few studies have reported the association of LV remodeling and sST2 in patients with HF. In a study of 100 patients, sST2 early after a MI correlated significantly with LV remodeling at baseline and functional recovery at 12 to 24 weeks. 19 In 139 dyspnic subjects with and without acute HF in the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study, sST2 was weakly associated with LV end-systolic volume (R 2 =0.04) but more strongly with LV ejection fraction (R 2 =0.13). 21 Whether the higher levels of sST2 during acute HF and MI are mediators of subsequent changes in LV structure or just a marker of the severity of the acute event is unclear. However, increased diastolic load was the predominant hemodynamic factor that contributed to sST2 production in pressure overload hypertrophy HF indicates heart failure; NRI, net reclassification improvement; and sST2, soluble ST2. *Estimated Cox model regression coefficients indicating the increase in natural logarithm of the hazard ratio per ng/mL of sST2 (95% confidence interval). NRI event is a change in sensitivity, and NRI no event is a change in specificity when 12-mo changes were added to the clinical model. Figure 5 . Curves depicting predicted survival times free of a morbid end point for a 5 ng/mL increase, 5 ng/mL decrease, or no change in soluble ST2 (sST2), adjusting for the average values for the 23 clinical covariates in the prediction model. Notice that the difference from the curve predicted when there is 0 change in sST2 is larger for a 5 ng/mL increase than a 5 ng/mL decrease, consistent with larger and significant regression coefficient for increasing values in Table 5 . and HF. 22 Although the heart, endothelium, and leukocytes express components of ST2/ST2 ligand/IL-33 pathway, the main source of circulating serum ST2 was extramyocardial. 22 Additional research is required to determine the exact relationship between sST2 and LV remodeling.
Sex and Baseline sST2
Analyses of baseline characteristics did not provide much insight into the observed sex differences in sST2. None of the previous studies tried to explain the sex difference, although Broch et al 7 reported that sex was an important correlate of sST2. More studies are required to address these interesting observations of sex differences. Meanwhile, these results suggest that the relationships between sST2 and patient outcomes are similar in women and men.
sST2 and Prognosis in HF
Measurements of sST2 added some significant prognostic information to a comprehensive clinical model to predict morbid events, with some potential net improvement in sensitivity and less so in specificity when using model-estimated individual predicted probabilities to identify patients who did or did not have an event during the first year of follow-up. However, most of the changes in estimated predicted probabilities may be too small to alter clinical decisions. It should be noted that this analysis is one of the few to include natriuretic peptides in the clinical model. When we excluded natriuretic peptides from the clinical model, Harrell C was reduced from 0.70 to 0.67.
Changes in sST2 Over Time and Outcomes
Perhaps, the most important and novel findings of this study are related to the changes in sST2 over time. On average, sST2 in the placebo group showed a significant upward trend for 12 months with no trend in the valsartan group. Because angiotensin-II is known to increase the expression of sST2, 3 these findings might reflect more effective blockade of the effect of angiotensin-II. However, baseline plasma renin activity and aldosterone were not related to the decreases in sST2 observed after 4 months in the valsartan group.
We found that increases in sST2 for 12 months were related to subsequent morbid events, whereas decreases in sST2 were not. If sST2 is used to monitor patients, a rise in sST2 may indicate a substantial increase in risk, whereas a decrease may not. Not surprisingly, the reassessment of sST2 and the clinical variables after 12 months provided better discrimination of subsequent outcomes than adding the 12-month change in sST2 to the baseline variables. Knowing by how much the sST2 level had decreased or increased at month 12 did not add significant prognostic information to the 12-month assessments alone. CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) was the only other study to report changes in sST2 in chronic HF. 8 In that study, the mean sST2 did not change for 3 months in either treatment group. Unlike this study, a fall in sST2 was associated with a reduced risk of hospitalization for HF, but an increase in sST2 was only weakly associated with cardiovascular hospitalizations. Differences in the magnitude and cause of the changes in sST2, as well as the methods of analyzing changes in sST2, may have contributed to these observed differences.
Strengths and Limitations
We used well-characterized patients in the Val-HeFT trial where outcomes were adjudicated. In addition, we were able to examine sST2 along with several established prognostic variables including NT-proBNP that provided good discrimination of patient outcomes before adding sST2. Although we report several state-of-practice statistical indices for evaluating prediction models, the individual predicted probabilities and predicted even-free survival curves that are most directly applicable to clinical practice ignore the uncertainty in the estimates as is often done when prediction models are used in clinical practice.
Conclusions
In this sample of patients with chronic HF, sST2 levels were mostly in the normal range. Nevertheless, sST2 was associated with features of worse HF and risk of adverse outcomes. Although levels of sST2 were higher in men compared with women, the relationships between sST2 and outcomes were similar. Compared with using clinical variables, baseline sST2 did not improve the ability to discriminate patients who did or did not have a poor outcome, although it did increase the sensitivity of 1-year outcome predictions. Increases in sST2 from baseline to 12 months were associated with an increased subsequent risk of poor outcomes and may be useful for monitoring patients. Additional studies are needed to understand how ST2 is related to the pathophysiology of HF and determine its value for improving patient outcomes.
